Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.54 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211424 | 1.00 | PIM1 (0.54) | PIM1PIM3PIM2HPGDPTPN1 | |
| SCHEMBL210424 | 0.80 | PIM1 (0.54) | PIM1PIM3PIM2HPGDPTPN1 | |
| SCHEMBL210423 | 0.80 | PIM1 (0.54) | PIM1PIM3PIM2HPGDPTPN1 | |
| SCHEMBL1065454 | 0.79 | F10 (0.49) | ALDH1A1MAPT | |
| SCHEMBL1061630 | 0.78 | F10 (0.48) | ALDH1A1MAPT | |
| SCHEMBL1753893 | 0.77 | MEN1 (0.50) | ALDH1A1MAPT | |
| SCHEMBL2829176 | 0.76 | POLB (0.56) | HPGDALDH1A1 | |
| SCHEMBL13949631 | 0.75 | HDAC1 (0.47) | — | |
| SCHEMBL13949633 | 0.75 | F10 (0.45) | ALDH1A1MAPT | |
| SCHEMBL13949629 | 0.75 | MEN1 (0.54) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | PIM1 2009/4885PIM3 2168/4885PIM2 2680/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | PIM1 2462/4885PIM3 2695/4885PIM2 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.